Safety Considerations for Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma

This segment focuses on the safety profile of subcutaneous daratumumab as observed in the AQUILA trial. Faculty review the incidence and types of adverse events, with particular attention to infections and other grade 3 or higher events, and discuss how these findings compare with the known safety experience of daratumumab in other disease settings.

Panelists explore practical considerations for monitoring and managing adverse events in an asymptomatic population, including patient selection, surveillance strategies, and supportive care measures. The discussion emphasizes the importance of risk–benefit assessment when initiating therapy in patients who may otherwise feel well.

By examining safety data alongside clinical experience, this segment highlights how tolerability considerations factor into real-world decision-making and informs conversations between clinicians and patients considering early intervention.